• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Q3 2024 results showed net income of $45.9 million, up 71% year-over-year, along with EBITDA of $119.1 million, up 55% year-over-year. Gross profit also rose to $286 million. GLP increased its ...

GLP-1 receptor agonists conferred greater HbA1c reductions in older adults than younger adults. Older adults had a lower risk for major adverse CV events than younger adults with SGLT2 inhibitors.

Demethylation is controlled by an esterase, PP2A methylesterase (PME-1). We tested two potential LCMT-1 small molecule inhibitors and found that methyl ...

However, with the widespread use of PD-1 inhibitors, there are increasing reports of immune-related adverse events (irAEs) in clinical practice, with immune-related hepatitis (IRH) being particularly ...

The analysis included 41,112 patients starting treatment with GLP-1 RAs; 76,093 starting a dipeptidyl peptidase-4 inhibitor (DPP4i); 43,499 starting a sodium-glucose cotransporter 2 inhibitor ...

Use of GLP-1RAs vs DPP-4 inhibitors was not associated with an increased risk for thyroid cancer. No evidence suggests increased thyroid cancer risk associated with use of glucagon-like peptide-1 ...

GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...

Busà Photography / Getty Images Many people believe that being wealthy means having a nice house, a late-model car, and a summer cottage, but the kind of money possessed by the wealthiest 1% of ...

Josh Gad is opening up about the weight loss success he’s had with GLP-1 medication — and sharing some of the conflicted feelings he’s had along the way. “I’m on a GLP-1 … this is the ...